You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma

    SBC: Oncosynergy, Inc.            Topic: 102

    PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus

    SBC: IDBIOLOGICS INC            Topic: NIAID

    The goal of this STTR is to provide a preclinically validated monoclonal antibody or antibody combination for the prevention of respiratory syncytial virusRSVin high risk patients including infants and the elderlyWorldwideof children are infected with RSV before the age ofresulting in an estimatedmillion lower respiratory tract infectionsIn the United States adults overhavemillion RSV infections c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Caveolae Targeted Cisplatin Immunoconjugates for Effective Lung Cancer Therapy

    SBC: Cavatar LLC            Topic: 102

    Abstract Caveolae at the endothelial cells surface can selectively rapidly and actively pump targeted antibodies out of the bloodstream and into underlying tissue in vivo even when they are conjugated to high molecular weight cargo Based on this exciting recent discovery we also found that caveolae pumping system enables unprecedented tumor specific targeting and penetration Taken together ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A universal vaccine for the prevention of meningococcal meningitis in Africa

    SBC: OMVAX INC            Topic: R

    For more than years sub Saharan Africa has suffered with high rates of endemic meningococcal disease and periodic epidemic epidemics involving over cases In a low cost serogroup A polysaccharide protein conjugate vaccine MenAfriVac was introduced in the region The vaccine confers protection against serogroup A MenA disease as well as asymptomatic nasopharyngeal MenA carria ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: O

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a debilitating complication that can arise from use of a number of chemotherapeutics and which limits both the dose and duration of cancer treatments with these agents Up to of cancer patients treated with chemotherapy describe some form of CIPN with sensory neuropathy being dominant Symptoms vary from tingling and numbne ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government